Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.48 |
| ▸ | ENPEP | Q07075 | 10/20 | 0.38 |
| ▸ | ANPEP | P15144 | 3/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.31 |
| ▸ | GRM6 | O15303 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27128551 | 1.00 | PTGS1 (0.48) | PTGS1SLC7A11ENPEPANPEPGABRR1 | |
| SCHEMBL1653844 | 0.89 | SLC22A6 (0.39) | PTGS1SLC7A11GABRR1LMNASLC22A6 | |
| Hydrochloric Acid SCHEMBL11804611 | 0.87 | SLC22A6 (0.38) | PTGS1SLC7A11GABRR1LMNASLC22A6 | |
| SCHEMBL20657045 | 0.87 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL1964879 | 0.87 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEP | |
| Hydrochloric Acid SCHEMBL11053790 | 0.84 | PTGS1 (0.52) | PTGS1SLC7A11ENPEPANPEP | |
| Hydrochloric Acid SCHEMBL11053789 | 0.84 | PTGS1 (0.52) | PTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL1235817 | 0.83 | PTGS1 (0.43) | PTGS1SLC7A11ENPEP | |
| SCHEMBL666315 | 0.83 | PTGS1 (0.43) | PTGS1SLC7A11ENPEP | |
| SCHEMBL6147913 | 0.83 | PTGS1 (0.43) | PTGS1SLC7A11ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107137724-B | Material for constructing temperature-responsive aggregate in cell and preparation method and application thereof | 国家纳米科学中心 | 2020-11-10 | — | — | CN | claimed |
| US-12599584-B2 | Indoline derivatives, compositions comprising them and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-04-14 | — | — | US | disclosed |
| CN-115531500-B | Composition for treating senile dementia and preparation method thereof | 河北以岭医药研究院有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20260022151-A1 | PHASE TRANSITION ADJUSTING ELEMENT AND USE THEREOF | UNIV TSINGHUA (CN) | 2026-01-22 | — | — | US | disclosed |
| US-20250345318-A1 | COMPOUND AND USE THEREOF IN PREVENTING OR TREATING RADIATION DAMAGE | SIMCERE PHARMACEUTICAL CO., LTD. (CN) | 2025-11-13 | — | — | US | disclosed |
| US-20250312408-A1 | NAP FOR SEX-SPECIFIC TREATMENT OF DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-10-09 | — | — | US | disclosed |
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2025-09-23 | — | — | US | disclosed |
| EP-4541823-A1 | PHASE CHANGE ADJUSTING ELEMENT AND USE THEREOF | Tsinghua University (CN) | 2025-04-23 | — | — | EP | disclosed |
| WO-2024230522-A1 | USE OF LACTIFLORIN IN PREPARATION OF DRUG FOR TREATING INFLAMMATORY BOWEL DISEASE | 安徽智博健生物医药科技有限责任公司 | 2024-11-14 | — | — | WO | disclosed |
| EP-3880304-B1 | COMPOSITIONS FOR TREATING OXIDATIVE STRESS-ASSOCIATED SKIN DISEASES AND SKIN AGEING | S BIOMEDIC NV (BE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2001090156-A2 | CARD DOMAIN CONTAINING POLYPEPTIDES, ENCODING NUCLEIC ACIDS, AND METHODS OF USE | THE BURNHAM INSTITUTE (US) | 2001-11-29 | — | — | WO | disclosed |
| US-20010041681-A1 | Therapeutically useful synthetic oligonucleotides | BIONICHE LIFE SCIENCES, INC. (CA) | 2001-11-15 | — | — | US | disclosed |
| WO-2001085153-A2 | POTENTIATION OF ANTINEOPLASTIC AGENTS USING SIGMA-2 LIGANDS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001044465-A2 | THERAPEUTICALLY USEFUL SYNTHETIC OLIGONUCLEOTIDES | BIONICHE LIFE SCIENCES INC. (CA) | 2001-06-21 | — | — | WO | disclosed |
| EP-1100933-A1 | NEW CASPASE HOMOLOGUE | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. (BE) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001016170-A2 | CARD PROTEINS INVOLVED IN CELL DEATH REGULATION | THE BURNHAM INSTITUTE (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-1003525-A1 | COMPOSITION AND METHOD FOR REGULATING CELL PROLIFERATION AND CELL DEATH | Bioniche Inc. (CA) | 2000-05-31 | — | — | EP | disclosed |
| EP-1002543-A1 | Pharmaceutical compositions for the therapy of glioma or prostate cell proliferative disorders containing cyclic rgd compounds | JCR PHARMACEUTICALS CO., LTD. (JP) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000004169-A1 | NEW CASPASE HOMOLOGUE | VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (BE) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999007383-A1 | COMPOSITION AND METHOD FOR REGULATING CELL PROLIFERATION AND CELL DEATH | BIONICHE INC. (CA) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | TNF, LITAF, PNLIP | PTGS1 474/4885SLC7A11 4377/4885ENPEP 1067/4885 |
| US-20250345318-A1 | COMPOUND AND USE THEREOF IN PREVENTING OR TREATING RADIATION DAMAGE | BAD, XPA, PARP14 | PTGS1 186/4885SLC7A11 3434/4885ENPEP 4231/4885 |
| US-12599584-B2 | Indoline derivatives, compositions comprising them and uses thereof | IL6, TNF, IDO1 | PTGS1 235/4885SLC7A11 450/4885ENPEP 424/4885 |
| US-20260022151-A1 | PHASE TRANSITION ADJUSTING ELEMENT AND USE THEREOF | SUMO3, SUMO1, SUMO2 | PTGS1 4320/4885SLC7A11 2371/4885ENPEP 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.